Predicted protein targets (top 9)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.54 |
| ▸ | GAA | P10253 | 1/20 | 0.54 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.54 |
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.54 |
| ▸ | ADRB2 | P07550 | 7/20 | 0.51 |
| ▸ | ADRB3 | P13945 | 10/20 | 0.48 |
| ▸ | ADRB1 | P08588 | 5/20 | 0.46 |
| ▸ | MEN1 | O00255 | 1/20 | 0.44 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.44 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL8842120 | 0.82 | ADRB2 (0.59) | ADRB2ADRB3ADRB1 | |
| SCHEMBL10725358 | 0.75 | KDM4E (0.54) | KDM4EGAASMN1; SMN2TDP1ADRB2 | |
| SCHEMBL15277792 | 0.74 | ADRB2 (0.69) | ADRB2ADRB3ADRB1 | |
| Oxalic Acid SCHEMBL7318481 | 0.74 | KDM4E (0.64) | KDM4EGAASMN1; SMN2TDP1ADRB2 | |
| Oxalic Acid SCHEMBL9239982 | 0.74 | KDM4E (0.64) | KDM4EGAASMN1; SMN2TDP1ADRB2 | |
| SCHEMBL10507768 | 0.74 | ADRB3 (0.69) | KDM4EGAASMN1; SMN2TDP1ADRB2 | |
| SCHEMBL9468370 | 0.73 | ADRB3 (0.68) | KDM4EGAASMN1; SMN2TDP1ADRB2 | |
| SCHEMBL10717538 | 0.72 | KDM4E (0.90) | KDM4EGAASMN1; SMN2TDP1ADRB2 | |
| SCHEMBL9239987 | 0.72 | KDM4E (0.55) | KDM4EGAASMN1; SMN2TDP1ADRB2 | |
| SCHEMBL7301591 | 0.72 | KDM4E (0.55) | KDM4EGAASMN1; SMN2TDP1ADRB2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 7 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-8062627-B2 | Bronchodilator; side efect reduction | SUNOVION PHARMACEUTICALS INC. (US) | 2011-11-22 | — | — | US | disclosed |
| US-20080161411-A1 | METHODS AND COMPOSITIONS FOR TREATING PULMONARY DISORDERS USING OPTICALLY PURE (R,R)-FORMOTEROL | SEPRACOR INC. (US) | 2008-07-03 | — | — | US | disclosed |
| US-7368120-B2 | Methods and compositions for treating pulmonary disorders using optically pure (R,R)-formoterol | SEPRACOR INC. (US) | 2008-05-06 | — | — | US | disclosed |
| US-20050131072-A1 | Methods and compositions for treating pulmonary disorders using optically pure (R,R)-formoterol | SEPRACOR INC. (US) | 2005-06-16 | — | — | US | disclosed |
| US-6866839-B2 | Methods and compositions for treating pulmonary disorders using optically pure (R,R)-formoterol | SEPRACOR INC. (US) | 2005-03-15 | — | — | US | disclosed |
| US-20030203970-A1 | Methods and compositions for treating pulmonary disorders using optically pure (R,R) -formoterol | SEPRACOR INC. (US) | 2003-10-30 | — | — | US | disclosed |
| US-6068833-A | ADMINISTERING TO A HUMAN SUFFERING FROM ASTHMA AN AMOUNT OF (R,R)-FORMOTEROL, OR A SALT TO CURE ASTHMA, CONTAINING 99% (R,R)-FORMOTEROL AND LESS THAN 1% (S,S)-FORMOTEROL; REDUCED HYPERSENSITIVITY | SEPRACOR INC. (US) | 2000-05-30 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20030203970-A1 | Methods and compositions for treating pulmonary disorders using optically pure (R,R) -formoterol | ADRB2, ADRB1, PTGIR | KDM4E 4852/4885GAA 3204/4885SMN1; SMN2 2376/4885 |
| US-20050131072-A1 | Methods and compositions for treating pulmonary disorders using optically pure (R,R)-formoterol | ADRB2, ADRB1, PTGIR | KDM4E 4852/4885GAA 3204/4885SMN1; SMN2 2376/4885 |
| US-20080161411-A1 | METHODS AND COMPOSITIONS FOR TREATING PULMONARY DISORDERS USING OPTICALLY PURE (R,R)-FORMOTEROL | ADRB2, ADRB1, PTGIR | KDM4E 4852/4885GAA 3204/4885SMN1; SMN2 2376/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.